Aroflo

Aroflo

Metered-Dose Inhaler (MDI)

🧬 Salmeterol + Fluticasone Propionate 🏢 Aristopharma Ltd.
Generic Name Salmeterol + Fluticasone Propionate
Manufacturer Aristopharma Ltd.
Unit Price 120 metered doses: ৳ 595.00

🔹 Indications

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Pharmacology

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Dosage & Administration

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Interaction

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Contraindications

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Side Effects

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Pregnancy & Lactation

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Precautions & Warnings

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Pediatric Usage

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Storage Conditions

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

💡 Frequently Asked Questions

Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled sho...
Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled sho...
Aroflo is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled sho...

User Reviews

No reviews yet!
Be the first to share your experience.

Write a Review